|
GB201609402D0
|
|
Materials and methods for treating cancer
|
|
GB201602934D0
|
|
Compounds
|
|
GB201600388D0
|
|
Inhibitors of ataxia-telangiectasia mutated and rad3-related protein kinase (ATR) for use in methods of treating cancer
|
|
GB201506248D0
|
|
Medical uses and methods for treating cancer using monopolar spindle 1 (MPS1) Kase Inhibitors
|
|
GB201420859D0
|
|
Tumour analysis
|
|
AU2014253528A1
|
|
Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
|
|
CA2922469A1
|
|
3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
|
|
GB201403496D0
|
|
Compounds and their therapeutic use
|
|
US2015329911A1
|
|
Nucleic acid biomarkers for prostate cancer
|
|
GB201316173D0
|
|
Compounds and their therapeutic use
|
|
GB201310917D0
|
|
Vaccinia virus for gene-directed enzyme prodrug therapy
|
|
AU2013206441A1
|
|
Location and stabilization device
|
|
EP2822656A1
|
|
3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
|
|
GB201220924D0
|
|
Materials and methods for determining susceptibility or predisposition to cancer
|
|
GB201218219D0
|
|
Nucleic acid biomarkers for prostate cancer
|
|
GB201213304D0
|
|
Ultrasonic imaging
|
|
GB201212690D0
|
|
Materials and methods for treating pten mutated or deficient cancer
|
|
GB201109966D0
|
|
Materials and methods for treating pten mutated or deficient cancer
|
|
GB201109965D0
|
|
Materials and methods for treating estrogen receptor alpher(ER) positive cancer
|
|
EP2399647A1
|
|
Radiotherapy system
|
